{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T07:12:30Z","timestamp":1765177950223,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jare.2019.11.008","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T02:41:07Z","timestamp":1574390467000},"page":"99-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Study of gender-related pharmacokinetics of ezogabine in Egyptian volunteers by a validated LC-MS\/MS bioanalytical method"],"prefix":"10.1016","volume":"22","author":[{"given":"Ehab F.","family":"Elkady","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed A.","family":"Aboelwafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa A.","family":"Fouad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2019.11.008_b0005","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1212\/WNL.0b013e31822cfc90","article-title":"Incidence of epilepsy: A systematic review and meta-analysis","volume":"77","author":"Ngugi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jare.2019.11.008_b0010","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1528-1167.2009.02481.x","article-title":"Estimation of the burden of active and life-time epilepsy: A meta-analytic approach","volume":"51","author":"Ngugi","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jare.2019.11.008_b0015","first-page":"42","article-title":"Antiepileptic drugs in development pipeline: A recent update","volume":"4","author":"Kaur","year":"2016","journal-title":"ENeurol Sci"},{"key":"10.1016\/j.jare.2019.11.008_b0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1528-1167.2008.01926.x","article-title":"Antiepileptic drugs during pregnancy: What is known and which AEDs seem to be safest?","volume":"49","author":"Pennell","year":"2008","journal-title":"Epilepsia."},{"key":"10.1016\/j.jare.2019.11.008_b0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1528-1167.2005.00411.x","article-title":"Sudden unexpected death in epilepsy: A review of incidence and risk factors","volume":"46","author":"Tomson","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.jare.2019.11.008_b0030","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.clinthera.2012.07.009","article-title":"Ezogabine (Retigabine) and its role in the treatment of partial-onset seizures: A review","volume":"34","author":"Splinter","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.jare.2019.11.008_b0035","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0090-9556(24)15258-0","article-title":"Metabolism of retigabine (D-23129), a novel anticonvulsant","volume":"27","author":"Hempel","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jare.2019.11.008_b0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0304-3940(00)00866-1","article-title":"The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2\/3 subunits","volume":"282","author":"Rundfeldt","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jare.2019.11.008_b0045","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1212\/WNL.0b013e3181fd6170","article-title":"RESTORE 2 Study Group, Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy","volume":"75","author":"Brodie","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jare.2019.11.008_b0050","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.0b013e3182194bd3","article-title":"RESTORE 1\/Study 301 Investigators, Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy","volume":"76","author":"French","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jare.2019.11.008_b0055","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/01.wnl.0000259034.45049.00","article-title":"205 Study Group, Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures","volume":"68","author":"Porter","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jare.2019.11.008_b0060","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/15748847113089990053","article-title":"Clinical pharmacokinetics of retigabine\/ezogabine","volume":"8","author":"Tompson","year":"2013","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.jare.2019.11.008_b0065","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/03009748109095328","article-title":"Pharmacokinetic factors influencing variability in human drug response","volume":"39","author":"Marchant","year":"1981","journal-title":"Scand J Rheumatol Suppl"},{"key":"10.1016\/j.jare.2019.11.008_b0070","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/bph.12362","article-title":"Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women","volume":"171","author":"Franconi","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jare.2019.11.008_b0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1067\/mcp.2003.12","article-title":"Effects of age and sex on the disposition of retigabine","volume":"73","author":"Hermann","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jare.2019.11.008_b0080","first-page":"7","article-title":"RP-HPLC method development and validation for the analysis of ezogabine in pharmaceutical dosage form","volume":"1","author":"Lakshmi","year":"2012","journal-title":"Int JA PS BMS"},{"key":"10.1016\/j.jare.2019.11.008_b0085","first-page":"955","article-title":"Validated RP-HPLC method for the estimation of ezogabine in tablet dosage form","volume":"3","author":"Satyanarayana","year":"2012","journal-title":"IJRPBS"},{"key":"10.1016\/j.jare.2019.11.008_b0090","first-page":"21","article-title":"An improved RP-HPLC method for the quantitative determination and validation of retigabine in bulk and pharmaceutical formulation","volume":"4","author":"Ravisankar","year":"2014","journal-title":"Int J Res Pharm Sci"},{"key":"10.1016\/j.jare.2019.11.008_b0095","first-page":"19","article-title":"Stability-indicating RP-HPLC method for the determination of ezogabine and identification of its degradation products","volume":"8","author":"Tamilselvi","year":"2016","journal-title":"J Pharm Sci Res"},{"key":"10.1016\/j.jare.2019.11.008_b0100","first-page":"241","article-title":"Development and validation of simple stability indicating HPLC method for the determination of retigabine and related substances in drug substances","volume":"24","author":"Xifeng","year":"2015","journal-title":"J Chin Pharm Sci"},{"key":"10.1016\/j.jare.2019.11.008_b0105","first-page":"1","article-title":"Development and validation of simple stability indicating LC method for analysis of ezogabine in bulk drug and pharmaceutical dosage form","volume":"2","author":"Pawanjeet","year":"2013","journal-title":"J Sci Res Pharm"},{"key":"10.1016\/j.jare.2019.11.008_b0110","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jchromb.2007.02.019","article-title":"Determination of N-acetyl retigabine in dog plasma by LC\/MS\/MS following off-line \u03bcElution 96-well solid phase extraction","volume":"852","author":"Bu","year":"2007","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.jare.2019.11.008_b0115","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1039\/C4AY02599G","article-title":"Development and validation of a quantitative method for determination of retigabine and its N-acetyl metabolite; overcoming challenges associated with circulating labile N-glucuronide metabolites","volume":"7","author":"Perez","year":"2015","journal-title":"Anal Methods"},{"key":"10.1016\/j.jare.2019.11.008_b0120","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jpba.2012.07.035","article-title":"Identification and characterization of four process-related impurities in retigabine","volume":"71","author":"Wang","year":"2012","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.jare.2019.11.008_b0125","unstructured":"Food and Drug Administration. Guidance for industry: bioanalytical method validation. U.S. Dep Heal Hum Serv 2001:4\u201310. http:\/\/www.labcompliance.de\/documents\/FDA\/FDA-Others\/Laboratory\/f-507-bioanalytical-4252fnl.pdf."},{"key":"10.1016\/j.jare.2019.11.008_b0130","unstructured":"EMA. Guideline on bioanalytical method validation, EMEA. Comm Med Prod Hum Use 2012;44:1\u201323. doi: EMEA\/CHMP\/EWP\/192217\/2009."},{"key":"10.1016\/j.jare.2019.11.008_b0135","first-page":"379","article-title":"Chapter 11 \u2013 statistical inference","author":"Fagerland","year":"2015","journal-title":"Res Med Biol Sci"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123219301869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123219301869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:46:15Z","timestamp":1761857175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123219301869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":27,"alternative-id":["S2090123219301869"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2019.11.008","relation":{},"ISSN":["2090-1232"],"issn-type":[{"type":"print","value":"2090-1232"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study of gender-related pharmacokinetics of ezogabine in Egyptian volunteers by a validated LC-MS\/MS bioanalytical method","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2019.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}